SIRPA and cancer: The result showed TAMs would receive activated signals from cancer cells through GAS6-AXL, RPS19-C5AR1, FAM3C-LAMP1, CD47-SIRPA, and VEGFA-NRP1/NRP2 L–R pairs in TME (Supplementary Table 5).